 Processa Pharmaceuticals Inc NASDAQ: PCSA has entered into a licensing agreement with Ocuphire Pharma Inc NASDAQ: OCUP to in-license RX-3117. RX-3117 is an oral anticancer agent with an improved pharmacological profile relative to gemcitabine and other nucleoside analogs. 